UHPLC Analysis of Intact Infliximab on BIOshell™ A400 Protein C4
Materials
related product
CONDITIONS
column
BIOshell A400 Protein C4; 10 cm x 2.1 mm I.D., 3.4 μm particles (66825-U)
mobile phase
[A] 70:25:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)
gradient
0% B to 100% B in 15 min
flow rate
0.2 mL/min
pressure
680 psi (46 Bar)
column temp.
75 °C
detector
UV, 215 nm
injection
5 μL
sample
Infliximab, 100 μg/mL, water (0.05% TFA)
Description
Analysis Note
Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell™ A400 Protein C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.
Legal Information
BIOshell is a trademark of Sigma-Aldrich Co. LLC